Resident's essay award: Alpha particle radio-immunotherapy: Animal models and clinical prospects

Roger M. Macklis, William D. Kaplan, James L M Ferrara, Robert W. Atcher, John J. Hines, Steven J. Burakoff, C. Norman Coleman

Research output: Contribution to journalArticle

Abstract

Short-lived isotopes that emit alpha particles have a number of physical characteristics which make them attractive candidates for radioimmunotherapy. Among these characteristics are high linear energy transfer and correspondingly high cytotoxicity; particle range limited to several cell diameters from the parent atom; low potential for repair of alpha-induced DNA damage; and low dependence on dose rate and oxygen enhancement effects. This report reviews the synthesis, testing and use in animal models of an alpha particle emitting radioimmunoconjugate constructed via the noncovalent chelation of Bismuth-212 to a monoclonal IgM antibody specific for the murine T cells/ neuroectodermal surface antigen, Thy 1.2. These 212Bi-anti-Thy 1.2 immunoconjugates are capable of extraordinary cytotoxicity in vitro, requiring approximately three 212Bi-labeled conjugates per target cell to suppress 3H-thymidine incorporation to background levels. The antigen specificity afforded by the monoclonal antibody contributes a factor of approximately 40 to the radiotoxicity of the immunoconjugate. Animals inoculated with a Thy 1.2+ malignant ascites were cured of their tumor in an antigen-specific fashion by intraperitoneal doses of approximately 200 μCi per mouse. Alpha particle emitting radioimmunoconjugates show great potential for regional and intracavitary molecular radiotherapy.

Original languageEnglish (US)
Pages (from-to)1377-1387
Number of pages11
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume16
Issue number6
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Immunoconjugates
Alpha Particles
animal models
antigens
Radio
Immunotherapy
alpha particles
Animal Models
antibodies
thymidine
dosage
linear energy transfer (LET)
chelation
Monoclonal Antibodies
Radioimmunotherapy
cells
Linear Energy Transfer
bismuth
Bismuth
mice

Keywords

  • Alpha particle radio-immunotherapy
  • Animal models
  • Bi-212
  • Immunoconjugates
  • Molecular radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Macklis, R. M., Kaplan, W. D., Ferrara, J. L. M., Atcher, R. W., Hines, J. J., Burakoff, S. J., & Coleman, C. N. (1989). Resident's essay award: Alpha particle radio-immunotherapy: Animal models and clinical prospects. International Journal of Radiation Oncology, Biology, Physics, 16(6), 1377-1387. https://doi.org/10.1016/0360-3016(89)90938-3

Resident's essay award : Alpha particle radio-immunotherapy: Animal models and clinical prospects. / Macklis, Roger M.; Kaplan, William D.; Ferrara, James L M; Atcher, Robert W.; Hines, John J.; Burakoff, Steven J.; Coleman, C. Norman.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 16, No. 6, 1989, p. 1377-1387.

Research output: Contribution to journalArticle

Macklis, Roger M. ; Kaplan, William D. ; Ferrara, James L M ; Atcher, Robert W. ; Hines, John J. ; Burakoff, Steven J. ; Coleman, C. Norman. / Resident's essay award : Alpha particle radio-immunotherapy: Animal models and clinical prospects. In: International Journal of Radiation Oncology, Biology, Physics. 1989 ; Vol. 16, No. 6. pp. 1377-1387.
@article{9f889eb24d3a4796835b82e9877879d5,
title = "Resident's essay award: Alpha particle radio-immunotherapy: Animal models and clinical prospects",
abstract = "Short-lived isotopes that emit alpha particles have a number of physical characteristics which make them attractive candidates for radioimmunotherapy. Among these characteristics are high linear energy transfer and correspondingly high cytotoxicity; particle range limited to several cell diameters from the parent atom; low potential for repair of alpha-induced DNA damage; and low dependence on dose rate and oxygen enhancement effects. This report reviews the synthesis, testing and use in animal models of an alpha particle emitting radioimmunoconjugate constructed via the noncovalent chelation of Bismuth-212 to a monoclonal IgM antibody specific for the murine T cells/ neuroectodermal surface antigen, Thy 1.2. These 212Bi-anti-Thy 1.2 immunoconjugates are capable of extraordinary cytotoxicity in vitro, requiring approximately three 212Bi-labeled conjugates per target cell to suppress 3H-thymidine incorporation to background levels. The antigen specificity afforded by the monoclonal antibody contributes a factor of approximately 40 to the radiotoxicity of the immunoconjugate. Animals inoculated with a Thy 1.2+ malignant ascites were cured of their tumor in an antigen-specific fashion by intraperitoneal doses of approximately 200 μCi per mouse. Alpha particle emitting radioimmunoconjugates show great potential for regional and intracavitary molecular radiotherapy.",
keywords = "Alpha particle radio-immunotherapy, Animal models, Bi-212, Immunoconjugates, Molecular radiotherapy",
author = "Macklis, {Roger M.} and Kaplan, {William D.} and Ferrara, {James L M} and Atcher, {Robert W.} and Hines, {John J.} and Burakoff, {Steven J.} and Coleman, {C. Norman}",
year = "1989",
doi = "10.1016/0360-3016(89)90938-3",
language = "English (US)",
volume = "16",
pages = "1377--1387",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Resident's essay award

T2 - Alpha particle radio-immunotherapy: Animal models and clinical prospects

AU - Macklis, Roger M.

AU - Kaplan, William D.

AU - Ferrara, James L M

AU - Atcher, Robert W.

AU - Hines, John J.

AU - Burakoff, Steven J.

AU - Coleman, C. Norman

PY - 1989

Y1 - 1989

N2 - Short-lived isotopes that emit alpha particles have a number of physical characteristics which make them attractive candidates for radioimmunotherapy. Among these characteristics are high linear energy transfer and correspondingly high cytotoxicity; particle range limited to several cell diameters from the parent atom; low potential for repair of alpha-induced DNA damage; and low dependence on dose rate and oxygen enhancement effects. This report reviews the synthesis, testing and use in animal models of an alpha particle emitting radioimmunoconjugate constructed via the noncovalent chelation of Bismuth-212 to a monoclonal IgM antibody specific for the murine T cells/ neuroectodermal surface antigen, Thy 1.2. These 212Bi-anti-Thy 1.2 immunoconjugates are capable of extraordinary cytotoxicity in vitro, requiring approximately three 212Bi-labeled conjugates per target cell to suppress 3H-thymidine incorporation to background levels. The antigen specificity afforded by the monoclonal antibody contributes a factor of approximately 40 to the radiotoxicity of the immunoconjugate. Animals inoculated with a Thy 1.2+ malignant ascites were cured of their tumor in an antigen-specific fashion by intraperitoneal doses of approximately 200 μCi per mouse. Alpha particle emitting radioimmunoconjugates show great potential for regional and intracavitary molecular radiotherapy.

AB - Short-lived isotopes that emit alpha particles have a number of physical characteristics which make them attractive candidates for radioimmunotherapy. Among these characteristics are high linear energy transfer and correspondingly high cytotoxicity; particle range limited to several cell diameters from the parent atom; low potential for repair of alpha-induced DNA damage; and low dependence on dose rate and oxygen enhancement effects. This report reviews the synthesis, testing and use in animal models of an alpha particle emitting radioimmunoconjugate constructed via the noncovalent chelation of Bismuth-212 to a monoclonal IgM antibody specific for the murine T cells/ neuroectodermal surface antigen, Thy 1.2. These 212Bi-anti-Thy 1.2 immunoconjugates are capable of extraordinary cytotoxicity in vitro, requiring approximately three 212Bi-labeled conjugates per target cell to suppress 3H-thymidine incorporation to background levels. The antigen specificity afforded by the monoclonal antibody contributes a factor of approximately 40 to the radiotoxicity of the immunoconjugate. Animals inoculated with a Thy 1.2+ malignant ascites were cured of their tumor in an antigen-specific fashion by intraperitoneal doses of approximately 200 μCi per mouse. Alpha particle emitting radioimmunoconjugates show great potential for regional and intracavitary molecular radiotherapy.

KW - Alpha particle radio-immunotherapy

KW - Animal models

KW - Bi-212

KW - Immunoconjugates

KW - Molecular radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0024343506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024343506&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(89)90938-3

DO - 10.1016/0360-3016(89)90938-3

M3 - Article

C2 - 2470706

AN - SCOPUS:0024343506

VL - 16

SP - 1377

EP - 1387

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 6

ER -